coronary restenosis


Also found in: Dictionary, Wikipedia.

coronary restenosis

The recurrence of narrowing of coronary arteries arter treatment by balloon angioplasty or other means. STENTING is reliably capable of preventing restenosis especially is antiproliferative-drug-eluting stents are used. In-stent restenosis is treated by intracoronary gamma and beta irradiation. Antisense therapies or gene therapy may prove important im managing restenosis.
Mentioned in ?
References in periodicals archive ?
Coronary restenosis is the undesirable re-closing of the coronary artery following angioplasty and stenting for atherosclerosis and is thought to occur as a result of physical damage to the endothelial layer of the blood vessel.
The available basic science research and experience with treatment of coronary restenosis justifies the treatment of restenosis in non-coronary stents.
The TAXUS program is a series of clinical studies designed to collect data on Boston Scientific's proprietary paclitaxel-eluting stent technology for reducing coronary restenosis, the growth of scar tissue within an artery after angioplasty and stenting.
The animals treated with iroxanadine showed significantly reduced coronary restenosis compared to the animals that did not receive drug treatment.
Zon has co-authored several investigational new drug (IND) applications related to antisense drugs for clinical studies of acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and coronary restenosis following balloon angioplasty.
The second study, titled "Site Specific Systemic Delivery of Rapamycin With Perfluorobutane Gas Microbubble Carrier Reduced Neointimal Formation in the Porcine Coronary Restenosis Model," was presented by Nicholas N.
The TAXUS clinical program is a series of studies designed to collect data on Boston Scientific's proprietary polymer-based, paclitaxel-eluting stent technology for reducing coronary restenosis, the growth of neointimal tissue within an artery after angioplasty and stenting.
AVI's chief executive officer, and AVI scientist, Derek Knapp will present data showing the efficacy of AVI's third-generation antisense drug, Resten-NG(TM), in preventing coronary restenosis, at the 25th annual conference of The Society for Cardiac Angiography and Interventions in Seattle.
The application is for the TAXUS IV clinical trial, the fourth in a series of studies designed to collect clinical information on BSC's proprietary technology for reducing coronary restenosis.
Food and Drug Administration (FDA) in support of BSC's application for an Investigational Device Exemption (IDE) for the TAXUS IV clinical trial, the fourth in a series of studies designed to collect clinical information on BSC's proprietary paclitaxel-eluting stent technology for reducing coronary restenosis.
CURRICULUM: Topics for discussion include Treatment of the Patient with Asymptomatic Valvular Heart Disease, Acute Coronary Syndromes, Coronary Restenosis, Syncope and Congestive Heart Failure.